29.51

1.63% -0.49

Arrivent Biopharma Inc (AVBP)

Overview News Price History Discussions Forecast

Arrivent Biopharma Inc stock is traded at $29.51, with a volume of 439.00K. It is down -1.63% in the last 24 hours and down -9.31% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

Previous Close:

$30.00

Open:

$29.99

24h Volume:

439.00K

Relative Volume:

0.80

Market Cap:

$1.37B

Revenue:

Net Income/Loss:

$-166.31M

P/E Ratio:

-6.6163

EPS:

-4.4602

Net Cash Flow:

$-160.59M

1W Performance:

-4.31%

1M Performance:

-9.31%

6M Performance:

+31.39%

1Y Performance:

+58.49%

1-Day Range:

$29.13

$30.07

1-Week Range:

$29.13

$31.60

52-Week Range:

$17.00

$35.83

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name

Arrivent Biopharma Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

240-780-6356

Address

18 CAMPUS BLVD., NEWTOWN SQUARE

Employee

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

AVBP's Discussions on Twitter

Compare AVBP vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVBP Arrivent Biopharma Inc	29.51	1.47B	0	-166.31M	-160.59M	-4.4602
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	BTIG Research	Buy
Dec-10-25	Initiated	BTIG Research	Buy
Nov-25-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Buy
Mar-20-25	Initiated	B. Riley Securities	Buy
Mar-10-25	Initiated	Guggenheim	Buy
Jul-22-24	Initiated	Oppenheimer	Outperform
Apr-30-24	Initiated	H.C. Wainwright	Buy
Feb-20-24	Initiated	Citigroup	Buy
Feb-20-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	Jefferies	Buy

View All

Arrivent Biopharma Inc Stock (AVBP) Latest News

Aug 13, 2026

ArriVent BioPharma (NASDAQ:AVBP) Receives "Buy" Rating from Guggenheim - MarketBeat

Aug 13, 2026

ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings - MarketBeat

Aug 13, 2026

ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target - TipRanks

Aug 13, 2026

ArriVent BioPharma's (AVBP) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat

Aug 13, 2026

Tema ETFs LLC Invests $1.98 Million in ArriVent BioPharma, Inc. $AVBP - MarketBeat

Aug 13, 2026

Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat

Aug 13, 2026

AVBP SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus

Aug 13, 2026

Aug 12, 2026

ArriVent BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

ArriVent BioPharma (NASDAQ:AVBP) Posts Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat

Aug 12, 2026

ArriVent inks China partnership for ARR-002 development - TipRanks

Aug 12, 2026

AVBP: Firmonertinib and novel ADCs show strong clinical progress, with major milestones ahead in 2026 - TradingView

Aug 12, 2026

ArriVent BioPharma (NASDAQ: AVBP) details $93M loss and $373M cash buffer - Stock Titan

Aug 12, 2026

ArriVent BioPharma reports $49.9 million Q2 net loss - quiverquant.com

Aug 12, 2026

ArriVent BioPharma Reports Second Quarter 2026 Financial Results - The Manila Times

Aug 12, 2026

ArriVent Expects Firmonertinib Lung Cancer Trial Data in 2H 2026 - Stock Titan

Aug 12, 2026

Aug 07, 2026

ArriVent BioPharma (AVBP) Expected to Release Quarterly Earnings on Friday - MarketBeat

Aug 07, 2026

Aug 05, 2026

Trading the Move, Not the Narrative: (AVBP) Edition - Stock Traders Daily

Aug 05, 2026

Aug 02, 2026

Seven Fleet Capital Management LP Buys New Shares in ArriVent BioPharma, Inc. $AVBP - MarketBeat

Aug 02, 2026

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Aug 02, 2026

Jul 31, 2026